Tvardi Therapeutics Appoints Michael Wyzga, Former CFO of Genzyme, to Board of Directors
Tvardi Therapeutics ("Tvardi") a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, today announced the appointment of Michael Wyzga, former Chief Financial Officer of Genzyme, to its Board of Directors. Mr. Wyzga brings decades of financial and operational pharmaceutical industry experience to the board. In conjunction with the appointment, Elan Ezickson will transition off the Board.
"First, we would like to thank Elan for his service to Tvardi from our nascency to now clinical proof of concept with our lead asset," said Imran Alibhai, Ph.D., Chief Executive Officer at Tvardi. "As Tvardi continues to evolve, we are thrilled to welcome Mike Wyzga to our Board of Directors. His years of experience in the biotech and pharma space, from leading companies to his role as CFO at Genzyme, give him unparalleled strategic and financial insight. We look forward to leveraging his expertise as we move our STAT3 inhibitors through the clinic."
Mr. Wyzga added, "I am honored to join Tvardi at this pivotal stage. With its lead asset, TT-01, already in the clinic for the treatment of cancer and additional promising indications in the pipeline for both oncology and fibrosis, the company is positioned to have substantial impact. I am looking forward to working with the Tvardi team and the Board to ensure the company achieves continued success."
Mr. Wyzga has spent the majority of his career in leadership roles in the biopharma industry. He served as Chief Financial Officer at Genzyme, stewarding the company through a myriad of transactions ultimately culminating in the acquisition of Genzyme by Sanofi for $20.1 billion. He also served as President, Chief Executive Officer and board member at Radius Health, a publicly traded biopharmaceutical company targeting osteoporosis. Mr. Wyzga received an M.B.A. from Providence College and a B.S. from Suffolk University.
About Tvardi Therapeutics, Inc.
Tvardi is a privately held, clinical-stage biopharmaceutical company developing small molecule inhibitors of STAT3. STAT3 is a key regulatory protein positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells as well as to the pathogenesis of many inflammatory and fibrotic diseases. Early clinical studies have shown that the company's lead asset in cancer, TTI-101, is well tolerated and has clinical activity across a broad range of tumors including multiple durable responses. To learn more, visit www.tvardi.com.